- Home
- PRTA vs MCI Comparison
PRTA vs MCI Comparison
Compare PRTA & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- MCI
- Stock Information
- Founded
- PRTA 2012
- MCI 1971
- Country
- PRTA Ireland
- MCI United States
- Employees
- PRTA N/A
- MCI N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- MCI Trusts Except Educational Religious and Charitable
- Sector
- PRTA Health Care
- MCI Finance
- Exchange
- PRTA Nasdaq
- MCI Nasdaq
- Market Cap
- PRTA 472.1M
- MCI 419.4M
- IPO Year
- PRTA N/A
- MCI N/A
- Fundamental
- Price
- PRTA $8.20
- MCI $21.81
- Analyst Decision
- PRTA Buy
- MCI
- Analyst Count
- PRTA 10
- MCI 0
- Target Price
- PRTA $14.86
- MCI N/A
- AVG Volume (30 Days)
- PRTA 1.2M
- MCI 40.4K
- Earning Date
- PRTA 08-04-2025
- MCI 01-01-0001
- Dividend Yield
- PRTA N/A
- MCI 8.46%
- EPS Growth
- PRTA N/A
- MCI N/A
- EPS
- PRTA N/A
- MCI 1.82
- Revenue
- PRTA $10,341,000.00
- MCI N/A
- Revenue This Year
- PRTA N/A
- MCI N/A
- Revenue Next Year
- PRTA $389.77
- MCI N/A
- P/E Ratio
- PRTA N/A
- MCI $9.88
- Revenue Growth
- PRTA N/A
- MCI N/A
- 52 Week Low
- PRTA $4.32
- MCI $12.96
- 52 Week High
- PRTA $22.83
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- PRTA 58.73
- MCI 66.09
- Support Level
- PRTA $8.05
- MCI $20.16
- Resistance Level
- PRTA $8.73
- MCI $21.90
- Average True Range (ATR)
- PRTA 0.38
- MCI 0.43
- MACD
- PRTA -0.05
- MCI 0.16
- Stochastic Oscillator
- PRTA 47.62
- MCI 94.83
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.